Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Verreault, Maite ^a   Strutt, Dita ^a   Masin, Dana ^a   Anantha, Malathi ^a   Yung, Andrew ^b   Kozlowski, Piotr ^b   Waterhouse, Dawn ^a   Bally, Marcel B ^a,b,c   Yapp, Donald T ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Centre for Drug Research and Development   (Canada)

Author keywords

endothelial cells; glioblastoma multiformevasculature normalizationliposomal drugs

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CD31 ANTIGEN; DOCETAXEL; DOXORUBICIN; HOE 33342; IRINOPHORE C; IRINOTECAN; LIPID; LIPOSOME; NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA BINDING PROTEIN; DRUG DERIVATIVE; RAG2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASEMENT MEMBRANE; BLOOD BRAIN BARRIER; BLOOD VESSEL DIAMETER; BLOOD VESSEL PERMEABILITY; BRAIN BLOOD FLOW; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICYTE; SINGLE DRUG DOSE; SUBCUTANEOUS TISSUE TUMOR; TUMOR VASCULARIZATION; ANIMAL; BRAIN TUMOR; CAPILLARY PERMEABILITY; CHEMISTRY; DRUG SCREENING; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE; TUMOR VOLUME; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CAMPTOTHECIN; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DNA-BINDING PROTEINS; DOXORUBICIN; GLIOBLASTOMA; HUMANS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MICE; MICE, KNOCKOUT; NANOPARTICLES; TUMOR BURDEN; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953757824     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-124     Document Type: Article

References (51)

1. Blasberg RG, Kobayashi T, Horowitz M, Rice JM, Groothuis D, Molnar P, Fenstermacher JD. Regional blood flow in ethylnitrosourea-induced brain tumors. Ann Neurol 1983, 14:189-201. 10.1002/ana.410140206, 6625536.
2. Groothuis DR, Pasternak JF, Fischer JM, Blasberg RG, Bigner DD, Vick NA. Regional measurements of blood flow in experimental RG-2 rat gliomas. Cancer Res 1983, 43:3362-7.
3. Vajkoczy P, Schilling L, Ullrich A, Schmiedek P, Menger MD. Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence microscopic approach in the athymic nude mouse. J Cereb Blood Flow Metab 1998, 18:510-20. 10.1097/00004647-199805000-00006, 9591843.
4. Baish JW, Gazit Y, Berk DA, Nozue M, Baxter LT, Jain RK. Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc Res 1996, 51:327-46. 10.1006/mvre.1996.0031, 8992232.
5. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 1994, 54:4564-8.
6. Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. J Neurooncol 2000, 50:99-108. 10.1023/A:1006474832189, 11245285.
7. Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, Webb MS, Waterhouse D, Bally MB. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clin Cancer Res 2008, 14:1208-17. 10.1158/1078-0432.CCR-07-0780, 18281556.
8. Baker JH, Lam J, Kyle AH, Sy J, Oliver T, Co SJ, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SS, Bally MB, Yapp DT. Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res 2008, 14:7260-71. 10.1158/1078-0432.CCR-08-0736, 19010842.
9. Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006, 290:H547-59. 10.1152/ajpheart.00616.2005, 16172161.
10. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-9. 10.1038/nm0901-987, 11533692.
11. Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer 1995, 71:482-8. 10.1038/bjc.1995.98, 2033637, 7880728.
12. Mabeta P, Pepper MS. A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. Angiogenesis 2009, 12:81-90. 10.1007/s10456-009-9134-8, 19214765.
13. Chen Q, Tong S, Dewhirst MW, Yuan F. Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Mol Cancer Ther 2004, 3:1311-7.
14. Arnold RD, Mager DE, Slack JE, Straubinger RM. Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin Cancer Res 2005, 11:8856-65. 10.1158/1078-0432.CCR-05-1365, 2883876, 16361575.
15. Zhou R, Mazurchuk R, Straubinger RM. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res 2002, 62:2561-6.
16. Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D, Bally M. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. Eur J Pharm Biopharm 2008, 68:607-17. 10.1016/j.ejpb.2007.08.011, 17904831.
17. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 1990, 50:575-9.
18. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989, 24:148-54. 10.1007/BF00300234, 2544306.
19. Lyng H, Dahle GA, Kaalhus O, Skretting A, Rofstad EK. Measurement of perfusion rate in human melanoma xenografts by contrast-enhanced magnetic resonance imaging. Magn Reson Med 1998, 40:89-98. 10.1002/mrm.1910400113, 9660558.
20. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10:223-32. 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S, 10508281.
21. Low J, Huang S, Blosser W, Dowless M, Burch J, Neubauer B, Stancato L. High-content imaging characterization of cell cycle therapeutics through in vitro and in vivo subpopulation analysis. Mol Cancer Ther 2008, 7:2455-63. 10.1158/1535-7163.MCT-08-0328, 18723491.
22. Stravopodis DJ, Karkoulis PK, Konstantakou EG, Melachroinou S, Lampidonis AD, Anastasiou D, Kachrilas S, Messini-Nikolaki N, Papassideri IS, Aravantinos G, Margaritis LH, Voutsinas GE. Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines. Int J Oncol 2009, 34:137-60.
23. Foroodi F, Duivenvoorden WC, Singh G. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells. Anticancer Drugs 2009, 20:115-22. 10.1097/CAD.0b013e32831c14ec, 19209028.
24. Saleh EM, El-Awady RA, Abdel Alim MA, Abdel Wahab AH. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells. Cell Biochem Biophys 2009, 55:95-105. 10.1007/s12013-009-9058-3, 19593673.
25. Landberg G, Tan EM, Roos G. Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: a new view of the cell cycle. Exp Cell Res 1990, 187:111-8. 10.1016/0014-4827(90)90124-S, 1967582.
26. Bernsen HJ, Rijken PF, Hagemeier NE, van der Kogel AJ. A quantitative analysis of vascularization and perfusion of human glioma xenografts at different implantation sites. Microvasc Res 1999, 57:244-57. 10.1006/mvre.1999.2143, 10329251.
27. Bernsen HJ, Rijken PF, Peters H, Raleigh JA, Jeuken JW, Wesseling P, van der Kogel AJ. Hypoxia in a human intracerebral glioma model. J Neurosurg 2000, 93:449-54. 10.3171/jns.2000.93.3.0449, 10969943.
28. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009, 27:2542-52. 10.1200/JCO.2008.19.9356, 2739611, 19332720.
29. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-63.
30. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005, 15:102-11. 10.1016/j.gde.2004.12.005, 15661540.
31. Yang Z, Suzuki R, Daniels SB, Brunquell CB, Sala CJ, Nishiyama A. NG2 glial cells provide a favorable substrate for growing axons. J Neurosci 2006, 26:3829-39. 10.1523/JNEUROSCI.4247-05.2006, 16597737.
32. Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, Viacava P, Naccarato AG, Kerbel RS, Danesi R, Del Tacca M, Allegrini G. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 2008, 98:1619-29. 10.1038/sj.bjc.6604352, 2391121, 18443598.
33. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002, 62:6938-43.
34. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009, 71:409-19. 10.1016/j.ejpb.2008.11.010, 19070661.
35. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007, 96:189-95. 2359994, 17211479.
36. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62. 10.1126/science.1104819, 15637262.
37. Le Serve AW, Hellmann K. Vascular changes in tumours after treatment with ICRF 159. Br J Pharmacol 1971, 43:457P-458P. 1665898, 5158233.
38. Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. Cancer Treat Res 2004, 117:249-62.
39. Deane BR, Lantos PL. The vasculature of experimental brain tumours. Part 1. A sequential light and electron microscope study of angiogenesis. J Neurol Sci 1981, 49:55-66. 10.1016/0022-510X(81)90188-X, 7205320.
40. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009, 69:5296-300. 10.1158/0008-5472.CAN-09-0814, 2824172, 19549889.
41. Ma J, Li S, Reed K, Guo P, Gallo JM. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. J Pharmacol Exp Ther 2003, 305:833-9. 10.1124/jpet.102.048587, 12626639.
42. Shapiro AB, Corder AB, Ling V. P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur J Biochem 1997, 250:115-21. 10.1111/j.1432-1033.1997.00115.x, 9431998.
43. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000, 105:1045-7. 10.1172/JCI9872, 300842, 10772648.
44. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878-86.
45. Cham KK, Baker JH, Takhar KS, Flexman JA, Wong MQ, Owen DA, Yung A, Kozlowski P, Reinsberg SA, Chu EM, Chang CW, Buczkowski AK, Chung SW, Scudamore CH, Minchinton AI, Yapp DT, Ng SS. Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer 2010, 103:52-60. 10.1038/sj.bjc.6605727, 20531411.
46. Vacca A, Ribatti D, Iurlaro M, Merchionne F, Nico B, Ria R, Dammacco F. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 2002, 11:103-18. 10.1089/152581602753448577, 11847007.
47. Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 1997, 25:1157-64.
48. Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 1996, 23:11-20.
49. Duyndam MC, van Berkel MP, Dorsman JC, Rockx DA, Pinedo HM, Boven E. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. Biochem Pharmacol 2007, 74:191-201. 10.1016/j.bcp.2007.04.003, 17498666.
50. Asai A, Shibui S, Barker M, Vanderlaan M, Gray JW, Hoshino T. Cell kinetics of rat 9L brain tumors determined by double labeling with iodo- and bromodeoxyuridine. J Neurosurg 1990, 73:254-8. 10.3171/jns.1990.73.2.0254, 2366082.
51. Wang F, Zhou F, Kruh GD, Gallo JM. Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncol 2010, 12:1043-9. 10.1093/neuonc/noq056, 20501632.